Literature DB >> 15334632

Heparanase expression in human colorectal cancer and its relationship to tumor angiogenesis, hematogenous metastasis, and prognosis.

Tomohiro Sato1, Akio Yamaguchi, Takanori Goi, Yasuo Hirono, Kazuo Takeuchi, Kanji Katayama, Shigeru Matsukawa.   

Abstract

BACKGROUND: Heparanase is considered to play an important role in tumor invasion and hematogenous metastasis. The aim of this study was to determine the expression of heparanase in colorectal cancer to evaluate its prognostic value.
METHODS: We analyzed heparanase mRNA derived from 130 colorectal cancer patients by reverse transcription polymerase chain reaction (PCR), compared its expression with clinicopathologic factors, and performed statistical analysis. To investigate the relationship between heparanase expression and tumor angiogenesis, 81 primary colorectal tumors were immunostained by use of a monoclonal anti-CD34 antibody.
RESULTS: Thirty three of 130 cancer tissues overexpressed heparanase. There were significant correlations between heparanase expression and serosal invasion, venous invasion, and liver metastasis. Multivariate analyzes revealed that heparanase mRNA overexpression was a significant independent risk factor for hematogenous metastasis in colorectal cancer. Among 104 patients who underwent curative resection, heparanase expression correlated with a high recurrence. The 5-year survival rate was 84.6% for patients with heparanase negative tumors, and 47.7% for those with heparanase overexpression; these differences between two groups of patients were significant. In multivariate analysis using the Cox regression model, heparanese expression emerged as an independent prognostic indicator. Moreover, the tumor angiogenesis of heparanase-positive tumors determined with a monoclonal anti-CD34 antibody was significantly higher than that of heparanase-negative tumors.
CONCLUSIONS: These results indicated that Heparanase expression may be an important role in invasion and hematogenous metastasis, and may be a biologic marker of prognostic significance in colorectal cancer patients. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15334632     DOI: 10.1002/jso.20097

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  24 in total

1.  Heparanase powers a chronic inflammatory circuit that promotes colitis-associated tumorigenesis in mice.

Authors:  Immanuel Lerner; Esther Hermano; Eyal Zcharia; Dina Rodkin; Raanan Bulvik; Victoria Doviner; Ariel M Rubinstein; Rivka Ishai-Michaeli; Ruth Atzmon; Yoav Sherman; Amichay Meirovitz; Tamar Peretz; Israel Vlodavsky; Michael Elkin
Journal:  J Clin Invest       Date:  2011-04-01       Impact factor: 14.808

2.  Heparanase enhances local and systemic osteolysis in multiple myeloma by upregulating the expression and secretion of RANKL.

Authors:  Yang Yang; Yongsheng Ren; Vishnu C Ramani; Li Nan; Larry J Suva; Ralph D Sanderson
Journal:  Cancer Res       Date:  2010-10-26       Impact factor: 12.701

3.  Significance of heparanase in cancer and inflammation.

Authors:  Israel Vlodavsky; Phillip Beckhove; Immanuel Lerner; Claudio Pisano; Amichai Meirovitz; Neta Ilan; Michael Elkin
Journal:  Cancer Microenviron       Date:  2011-08-03

4.  Heparanase localization and expression by head and neck cancer: correlation with tumor progression and patient survival.

Authors:  Ilana Doweck; Victoria Kaplan-Cohen; Inna Naroditsky; Edmond Sabo; Neta Ilan; Israel Vlodavsky
Journal:  Neoplasia       Date:  2006-12       Impact factor: 5.715

5.  Nuclear heparanase-1 activity suppresses melanoma progression via its DNA-binding affinity.

Authors:  Y Yang; C Gorzelanny; A T Bauer; N Halter; D Komljenovic; T Bäuerle; L Borsig; M Roblek; S W Schneider
Journal:  Oncogene       Date:  2015-03-09       Impact factor: 9.867

6.  Heparanase expression in malignant salivary gland tumors inversely correlates with long-term survival.

Authors:  Ofer Ben-Izhak; Victoria Kaplan-Cohen; Neta Ilan; Shlomit Gan; Israel Vlodavsky; Rafael Nagler
Journal:  Neoplasia       Date:  2006-10       Impact factor: 5.715

Review 7.  Mechanisms of heparanase inhibitors in cancer therapy.

Authors:  Benjamin Heyman; Yiping Yang
Journal:  Exp Hematol       Date:  2016-08-26       Impact factor: 3.084

8.  Expression and clinical significance of heparanase in neuroblastoma.

Authors:  Li-Duan Zheng; Qiang-Song Tong; Shao-Tao Tang; Zhi-Yong Du; Yuan Liu; Guo-Song Jiang; Jia-Bin Cai
Journal:  World J Pediatr       Date:  2009-08-20       Impact factor: 2.764

9.  Heparanase induces VEGF C and facilitates tumor lymphangiogenesis.

Authors:  Victoria Cohen-Kaplan; Inna Naroditsky; Anna Zetser; Neta Ilan; Israel Vlodavsky; Ilana Doweck
Journal:  Int J Cancer       Date:  2008-12-01       Impact factor: 7.396

Review 10.  Heparanase enzyme in chronic inflammatory bowel disease and colon cancer.

Authors:  Esther Hermano; Immanuel Lerner; Michael Elkin
Journal:  Cell Mol Life Sci       Date:  2012-02-14       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.